1. Generics Bulletin

Global development path proposed to ICH by FDA

Aset of “internationally harmonised guidelines on scientific and technical standards for generic drugs” should be developed through the International Council forHarmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), according to a proposal that has been put forward by the US Food and Drug Administration (FDA).

Aset of “internationally harmonised guidelines on scientific and technical standards for generic drugs” should be developed through the International Council forHarmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), according to a proposal that has been put forward by the US Food and Drug Administration (FDA).

“The idea is straightforward,” explained FDA Commissioner Scott Gottlieb. “Generic drug developers should be able to implement a single global...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

Zentiva Strikes Deal With Aboca To Expand CHC Offering

 
• By Tom Gallen

Czech Republic's Zentiva snaps up Aboca portfolio adding supplement brands marketed in European countries such France, Italy and Spain.

Will Amarin Finally Launch An Authorized Generic Version Of Vascepa?

 
• By Dean Rudge

As it offloads commercial rights to the brand in Europe, Amarin has for the umpteenth time teased the possibility of launching an authorized generic version of Vascepa in the US.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)